Technical Analysis for ASND - Ascendis Pharma A/S
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
 |
73.39 | -0.10% | -0.07 |
ASND closed down 0.1 percent on Thursday, January 17, 2019, on 1.13 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| See historical ASND trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Jan 17 | New Uptrend | Bullish | 0.00% |
| Jan 17 | NR7 | Range Contraction | 0.00% |
| Jan 17 | Inside Day | Range Contraction | 0.00% |
| Jan 17 | Wide Bands | Range Expansion | 0.00% |
| Jan 17 | Overbought Stochastic | Strength | 0.00% |
| Jan 16 | Wide Bands | Range Expansion | -0.10% |
| Jan 16 | Overbought Stochastic | Strength | -0.10% |
| Jan 15 | Wide Bands | Range Expansion | -1.78% |
| Jan 15 | Overbought Stochastic | Strength | -1.78% |
| Jan 15 | Upper Bollinger Band Touch | Strength | -1.78% |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2018-11-28
- Sector: Healthcare
- Industry: Bio Therapeutic Drugs
Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies to treat unmet medical needs. It is developing TransCon human growth hormone that has completed Phase II clinical trials in adults to treat growth hormone deficiency (GHD) and other indications, as well as in Phase II studies in children for treating GHD; and TransCon Treprostinil for the treatment of pulmonary arterial hypertension, a life-threatening disease characterized by elevated blood pressure in the pulmonary arteries. The company is also developing TransCon Insulin for the treatment of diabetes; and TransCon Ranibizumab, a compound to support ranibizumab injection. It has strategic collaborations with Sanofi, Genentech, and United Therapeutics Corporation. The company was founded in 2006 and is headquartered in Hellerup, Denmark.
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more ASND news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 76.99 |
| 52 Week Low | 48.0 |
| Average Volume | 138,564 |
| 200-Day Moving Average | 66.0945 |
| 50-Day Moving Average | 63.5631 |
| 20-Day Moving Average | 65.6373 |
| 10-Day Moving Average | 70.725 |
| Average True Range | 3.4561 |
| ADX | 26.71 |
| +DI | 29.3965 |
| -DI | 9.9713 |
| Chandelier Exit (Long, 3 ATRs ) | 65.4617 |
| Chandelier Exit (Short, 3 ATRs ) | 65.0333 |
| Upper Bollinger Band | 77.3248 |
| Lower Bollinger Band | 53.9498 |
| Percent B (%b) | 0.83 |
| BandWidth | 35.612373 |
| MACD Line | 2.9869 |
| MACD Signal Line | 1.9929 |
| MACD Histogram | 0.994 |
| Fundamentals | Value |
|---|---|
| Market Cap | 2.39 Billion |
| Num Shares | 32.5 Million |
| EPS | -3.61 |
| Price-to-Earnings (P/E) Ratio | -20.33 |
| Price-to-Sales | 288.07 |
| Price-to-Book | 6.90 |
| PEG Ratio | -0.32 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 76.32 | ||||
| Resistance 3 (R3) | 76.53 | 75.76 | 75.83 | ||
| Resistance 2 (R2) | 75.76 | 75.02 | 75.66 | 75.66 | |
| Resistance 1 (R1) | 74.58 | 74.56 | 75.17 | 74.37 | 75.50 |
| Pivot Point | 73.81 | 73.81 | 74.11 | 73.71 | 73.81 |
| Support 1 (S1) | 72.63 | 73.07 | 73.22 | 72.42 | 71.28 |
| Support 2 (S2) | 71.86 | 72.61 | 71.76 | 71.12 | |
| Support 3 (S3) | 70.68 | 71.86 | 70.95 | ||
| Support 4 (S4) | 70.47 |
